Darunavir and Rilpivirine Interactions With Levonorgestrel Implant

Overview

This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when used in combination with Levonorgestrel

Full Title of Study: “A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-based Antiretroviral Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2019

Detailed Description

Despite the benefits of hormonal contraceptives, significant drug-drug interactions (DDIs) with some antiretroviral therapies (ART) represent a barrier to effective family planning methods for HIV-infected women. It is therefore critical to generate data on the combined use of hormonal contraceptives and ART. This study is a prospective, non-randomized, open-label, parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel (LNG) PK parameters in two treatment groups (rilpivirine or darunavir- based ART) in 60 HIV-1 infected women. The primary endpoint is the comparison of the mean LNG concentrations at month 6 between the rilpivirine or darunavir treatment groups versus historical controls. This study will provide information on effective ART options for HIV positive women who opt for the contraceptive implant as a family planning method of choice.

Interventions

  • Drug: Levonorgestrel two rod sub-dermal implant
    • Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
  • Drug: Rilpivirine
    • Oral ripilvirine 25mg once daily
  • Drug: Darunavir+Ritonavir
    • Oral DRV/r 600/100mg twice daily

Arms, Groups and Cohorts

  • Experimental: Rilpivirine arm
    • All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
  • Experimental: Darunavir arm
    • All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period

Clinical Trial Outcome Measures

Primary Measures

  • Levonorgestrel concentrations: Change in mean levonorgestrel (LNG) concentrations
    • Time Frame: 6 months
    • Comparison of the mean levonorgestrel (LNG) concentrations at month 6 between the rilpivirine (RPV) or darunavir (DRV) treatment groups versus historical controls

Secondary Measures

  • Change in mean rilpivirine concentration
    • Time Frame: 12 months
    • Rilpivirine mean concentration change prior to implant placement and then over the duration of the study time period.
  • Change in mean darunavir concentration
    • Time Frame: 12 months
    • Darunavir mean concentration change prior to implant placement and then over the duration of the study time period.
  • Adverse events
    • Time Frame: 12 months
    • Any signs and symptoms related to hormone exposure, including abnormal vaginal bleeding and local or systemic adverse events observed during the study period in both study groups.

Participating in This Clinical Trial

Inclusion Criteria

1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study. 2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. Women age 18 years to 45 years 4. Diagnosed with HIV infection 5. Medically eligible for the LNG subdermal implant as a contraceptive method based on the WHO Medical Eligibility Criteria for Contraceptive Use11 6. Receiving EFV- or LPV/r-based ART for a minimum of 1 year 7. If not abstinent, must agree to use an effective non-hormonal method of contraception for the duration of the study including male and female condoms or the copper-T intrauterine device. 8. Participants must have a negative urine pregnancy test at entry and report no unprotected sex since the last menstrual period or in the last two weeks. - Exclusion Criteria:

1. HIV RNA greater than 50 copies/mL at the screening visit 2. CD4 count below 200 cells/mm3 at the screening visit 3. History of virologic failure on the current regimen (two consecutive viral load results equal to or greater than 400 copies/mL) 4. Serum hemoglobin less than 9.0 g/dl at screening 5. Elevations in serum levels of alanine transaminase (ALT) above 5 times the upper limit of normal 6. Elevations in serum creatinine above 2.5 times the upper limit of normal 7. Use of drugs known to be contraindicated with LNG, RPV (for women taking EFV-based ART), or DRV (for women taking LPV-based ART) within 30 days of study entry. Due to the dynamic nature of drug interactions related to antiretroviral therapy, the study team will review all concomitant medications at screening based on the US Department of Health and Human Services drug interaction table 14 and the University of Liverpool HIV drug interaction tables (www.hiv-druginteractions.org) 8. Currently pregnant or postpartum <30 days at study entry. 9. Breastfeeding women within 6 months of delivery. 10. Patients with a history of hypersensitivity to LNG implant, undiagnosed vaginal bleeding, diagnosed or suspected sex hormone dependent neoplasia, benign or malignant liver tumor, or thromboembolic disease. 11. Presence of any active clinically significant disease or life-threatening disease that, in the investigator's opinion, would compromise the subject's safety or outcome of the study. -

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Makerere University
  • Collaborator
    • University of Nebraska
  • Provider of Information About this Clinical Study
    • Principal Investigator: Infectious Diseases Institute, Head of Department, Prevention Care and Treatment Infectious Diseases Institute, Makerere University College of Health Sciences – Makerere University
  • Overall Official(s)
    • Mohammed Lamorde, PhD, Principal Investigator, Infectious Diseases Institute
  • Overall Contact(s)
    • Senior Research Manager, 0704817590, sokoboi@idi.co.ug

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.